Archives — September 2016 back to current month (4)
Australian regenerative medicine company Regeneus Ltd. has a handful of stock-moving Q4/16 catalysts on the calendar, among them a potential licensing agreement for its mesenchymal stem cell technology in Japan.
Imagin, a Better Way to Detect Bladder Cancer (09/20/2016)
Bob Moriarty profiles Imagin Medical, a company that has developed a new way of detecting bladder cancer through endoscopes.
Regeneus Secures Government Funding for R&D (09/14/2016)
The Australian government has bolstered Regeneus, a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding.
Three Shots on Goal in Q4/16 for DURECT Corp. (09/08/2016)
With a trifecta of share-moving milestones anticipated in Q4/16, including possible FDA approval of abuse-resistant opioid Remoxy, Laidlaw & Co. Analyst Jim Molloy sees blue sky ahead for DURECT Corp.
|"INO's pro forma cash position after the offering could be around $160M and should be sufficient for 18 months of operations; we reiterate our Buy rating."|
|"We believe that VIVE is currently in discussion with the agency and that a formal IDE would be submitted in the coming months such that a study (VIVEVE II) would commence in late 2017."|